ARTV: artivabio.com Company Value to Net Income

Artiva Biotherapeutics - graphic logo of issuer ARTV

The market price for Artiva Biotherapeutics, Inc. (ARTV) shown on this chart with the -2.00 indicator is driven by the use of advanced mass-production technologies for biologics and alliances with global pharmaceutical companies. The development of off-the-shelf NK cells for tumor therapy is currently in its peak efficiency phase ahead of major releases. However, the business faces high production costs and a reliance on external financing during the early stages of clinical trials.

Price to Earnings Ratio: Artiva (ARTV) for 03/26/2025 - 11/18/2026

Comprehensive metric breakdowns and analytics for Artiva Biotherapeutics Inc. (ARTV)

Summary company analysis:ARTV, Artiva Biotherapeutics Inc.
Flagship merchandise of Artiva Biotherapeutics

The P/E ratio measures a business's market value relative to its earnings, providing a real-time assessment of liquidity risks and debt service costs through demand imbalances prior to the publication of financial statements. By analyzing the P/E history of Artiva Biotherapeutics, Inc. (ARTV), an investor can evaluate the stability of its capitalization, where high asset values are supported by the strategic retention of key NK-cell therapy developers and the recruitment of biomanufacturing experts.

Analysis of competing companies

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme Inc.)|RVMD (RevMed) - Company Value to Net Income|P/E Multiple AAPG (ascentage.com)|CGON - Price to Earnings Ratio|URGN: Price to Earnings Ratio|BCAX - P/E Multiple|Personalis Corp (PSNL) - Price to Earnings Ratio|Erasca Corp - Company Value to Net Income|DCTH (Delcath Systems Inc) - P/E Multiple|Market Cap to Earnings Y-mAbs Therapeutics, Inc. YMAB|P/E Multiple AURA|Price to Earnings Ratio Candel Therapeutics, Inc. CADL|P/E Multiple ARAY (Accuray, Inc.)|SELLAS Life Sciences - Price to Earnings Ratio|ACTU: Price to Earnings Ratio|Citius Oncology, Inc. - Market Price to Net Income Ratio|HURA (TuHURA Biosciences) - Price to Earnings Ratio|TARA: Market Price to Net Income Ratio|Price to Earnings Ratio FATE|WHWK: Company Value to Net Income|Price to Earnings Ratio TCRX (TScan Therapeutics Inc)|Business Payback Period Champions Oncology Inc|P/E Multiple XBIT (XBiotech Inc.)|Company Value to Net Income CVM|OS Therapies Inc. - P/E Multiple|RADX - P/E Multiple|ANL (adlainortye.com) - Price to Earnings Ratio|VERU - Business Payback Period|TPST (Tempest Therapeutics, Inc.) - P/E Multiple|P/E Multiple xiliotx.com|Price to Earnings Ratio Enochian BioSciences (RENB)|Price to Earnings Ratio MURA (Mural Oncology PLC)|Price to Earnings Ratio Kairos Pharma Ltd KAPA|P/E Multiple OnKure Therapeutics Inc OKUR|CytoMed Therapeutics - P/E Multiple|Business Payback Period Curis CRIS|APLM: P/E Multiple|Price to Earnings Ratio Tharimmune, Inc.|ADVB (Advanced Biomed) - P/E Multiple|Genprex - Market Cap to Net Income|Price to Earnings Ratio calidibio.com (CLDI)|SBFM (Sunshine Biopharma Inc.) - Company Value to Net Income|P/E Multiple XBIO (Xenetic Biosciences)|Salarius Pharmaceuticals (SLRX) - Market Cap to Earnings|PPBT: Price to Earnings Ratio|Company Value to Net Income AONC (American Oncology Network, Inc.)|BeOne Medicines (BGNE) - Price to Earnings Ratio|Checkpoint Therapeutics, Inc (CKPT) - P/E Multiple|Price to Earnings Ratio Elevation Oncology, Inc.|ICAD: Company Value to Net Income|Price to Earnings Ratio ikenaoncology.com (IKNA)|Price to Earnings Ratio NTBL (Notable Labs, Ltd.)|P/E Multiple VIRX (viracta.com)|MOR - Price to Earnings Ratio|NAYA - Price to Earnings Ratio|Market Cap to Net Income AAPGV